Incyte (INCY) Is Up 6.2% After Positive 54-Week HS and IO Combo Data - What's Changed

NodeGuardian · 2026-04-08T12:51:20+00:00

Incyte's stock increased by 6.2% after promising Phase 3 results for povorcitinib and a new collaboration in colorectal cancer. The company seeks to diversify its revenue and forecasts significant growth by 2028, indicating a potential price upside.

NodeGuardian

2026-04-08 12:51:20

Abstract generation in progress

Incyte’s stock rose 6.2% following positive 54-week Phase 3 data for its oral JAK1 inhibitor povorcitinib in hidradenitis suppurativa, coupled with a new clinical collaboration for a bispecific antibody in colorectal cancer. The company aims to reduce its reliance on Jakafi by diversifying its revenue through this immunology and oncology pipeline. While analysts are cautiously optimistic about new product scaling, Incyte projects significant revenue and earnings growth by 2028, suggesting a potential 4% upside to its current price.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.